We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
A filing was submitted.
Consensus vs. actual, and revenue trend
Consensus PT $55.9 · 9 analysts
Stored first · Google News · Yahoo Finance (English)
Lakefront Biotherapeutics director resigns for Sanofi role - Investing.com
Lakefront Biotherapeutics director resigns for Sanofi role Investing.com
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi - The Manila Times
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi The Manila Times
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi
Enable Injections’ On-Body Injector Wins FDA Nod to Deliver Sanofi Anticancer Drug - Medical Product Outsourcing
Enable Injections’ On-Body Injector Wins FDA Nod to Deliver Sanofi Anticancer Drug Medical Product Outsourcing
Pharmalittle: We're reading about an RFK Jr. push against psychiatric meds, a Sanofi blood cancer drug, and more - STAT
Pharmalittle: We're reading about an RFK Jr. push against psychiatric meds, a Sanofi blood cancer drug, and more STAT
SANOFI : UBS reiterates its Neutral rating - marketscreener.com
SANOFI : UBS reiterates its Neutral rating marketscreener.com
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 30. | After market close (AMC) | $1.13 | — | — | $11B | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 01. 16. | UBS | — | Downgrade | Buy → Neutral | — | UBS: Buy → Neutral |
| 2026. 01. 07. | Barclays | — | Downgrade | Overweight → Equal-Weight | — | Barclays: Overweight → Equal-Weight |
| 2025. 12. 09. | Guggenheim | — | Downgrade | Buy → Neutral | — | Guggenheim: Buy → Neutral |
| 2025. 12. 08. | JP Morgan | — | Downgrade | Overweight → Neutral | — | JP Morgan: Overweight → Neutral |
| 2025. 09. 08. | Morgan Stanley | — | Upgrade | Equal-Weight → Overweight | — | Morgan Stanley: Equal-Weight → Overweight |
| 2025. 09. 03. | Deutsche Bank | — | Upgrade | Hold → Buy | — | Deutsche Bank: Hold → Buy |
Price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 331,765 | $16.08M | 0.03% | — | New position |